Eyenovia Provides Clinical and Scientific Update On FDA-Approved Products Mydcombi And Clobetasol Propionate Ophthalmic Suspension
Eyenovia Provides Clinical and Scientific Update On FDA-Approved Products Mydcombi And Clobetasol Propionate Ophthalmic Suspension
Eyenovia 提供美國食品藥品管理局批准的產品 Mydcombi 和 Clobetasol 丙酸鹽眼用懸浮液的臨床和科學最新情況
- Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8μL spray per eye)
- Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the Optejet.
- 公司公佈了Mydcombi的IV期研究結果，該研究旨在描述最低可交付劑量（每隻眼睛一支8μL噴霧劑）的療效和持續時間
- 還宣佈ARVO即將發佈的關於氯倍他索背後的獨特技術的演講，該技術允許將來的眼科懸浮液與Optejet一起使用。